220 related articles for article (PubMed ID: 23585192)
41. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
[TBL] [Abstract][Full Text] [Related]
43. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
44. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Perez EA; Romond EH; Suman VJ; Jeong JH; Davidson NE; Geyer CE; Martino S; Mamounas EP; Kaufman PA; Wolmark N
J Clin Oncol; 2011 Sep; 29(25):3366-73. PubMed ID: 21768458
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
46. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
47. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
Caparica R; Ma Y; De Angelis C; Richard F; Desmedt C; Awada A; Piccart M; Perez EA; Moreno-Aspitia A; Badve S; Thompson EA; de Azambuja E
Clin Breast Cancer; 2022 Jun; 22(4):308-318. PubMed ID: 34980541
[TBL] [Abstract][Full Text] [Related]
48. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
49. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
50. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer.
Hayashi N; Niikura N; Yamauchi H; Nakamura S; Ueno NT
Breast Cancer Res Treat; 2013 Jan; 137(2):523-31. PubMed ID: 23184079
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Sendur MA; Aksoy S; Zengin N; Altundag K
Br J Cancer; 2012 Nov; 107(11):1815-9. PubMed ID: 23099804
[TBL] [Abstract][Full Text] [Related]
52. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
54. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
55. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab.
Wang X; Cai L; Ye F; Li M; Ma L; Geng C; Song Z; Liu Y
Medicine (Baltimore); 2019 Sep; 98(36):e16937. PubMed ID: 31490377
[TBL] [Abstract][Full Text] [Related]
56. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ; Procter M; Leyland-Jones B; Goldhirsch A; Untch M; Smith I; Gianni L; Baselga J; Bell R; Jackisch C; Cameron D; Dowsett M; Barrios CH; Steger G; Huang CS; Andersson M; Inbar M; Lichinitser M; Láng I; Nitz U; Iwata H; Thomssen C; Lohrisch C; Suter TM; Rüschoff J; Suto T; Greatorex V; Ward C; Straehle C; McFadden E; Dolci MS; Gelber RD;
N Engl J Med; 2005 Oct; 353(16):1659-72. PubMed ID: 16236737
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
[TBL] [Abstract][Full Text] [Related]
58. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Zhou Q; Yin W; Du Y; Lu J
PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
[TBL] [Abstract][Full Text] [Related]
59. Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
He X; Ji J; Tian M; Esteva FJ; Hortobagyi GN; Yeung SJ
Clin Cancer Res; 2019 Dec; 25(24):7388-7395. PubMed ID: 31515457
[TBL] [Abstract][Full Text] [Related]
60. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
Untch M; Gelber RD; Jackisch C; Procter M; Baselga J; Bell R; Cameron D; Bari M; Smith I; Leyland-Jones B; de Azambuja E; Wermuth P; Khasanov R; Feng-Yi F; Constantin C; Mayordomo JI; Su CH; Yu SY; Lluch A; Senkus-Konefka E; Price C; Haslbauer F; Suarez Sahui T; Srimuninnimit V; Colleoni M; Coates AS; Piccart-Gebhart MJ; Goldhirsch A;
Ann Oncol; 2008 Jun; 19(6):1090-6. PubMed ID: 18296421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
